Put the Vanc Down, Flip It and Reverse It: Comparison of Vancomycin and Daptomycin Health Care Utilization and Cost in Outpatient Parenteral Antimicrobial Therapy

Amber C Streifel; Katie Luis; Monark Nakrani; Diana Yu; Monica K Sikka; Cara D Varley; Alyse Douglass; Heather Mayer; Kathleen Young; James S Lewis 2nd

doi:10.1093/ofid/ofae438

Put the Vanc Down, Flip It and Reverse It: Comparison of Vancomycin and Daptomycin Health Care Utilization and Cost in Outpatient Parenteral Antimicrobial Therapy

Open Forum Infect Dis. 2024 Jul 25;11(8):ofae438. doi: 10.1093/ofid/ofae438. eCollection 2024 Aug.

Authors

Affiliations

¹ Department of Pharmacy, Oregon Health & Science University, Portland, Oregon, USA.
² Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
³ Epidemiology Programs, School of Public Health, Oregon Health & Science University-Portland State University, Portland, Oregon, USA.

Abstract

Vancomycin and daptomycin are frequently used in outpatient parenteral antimicrobial therapy (OPAT). We analyze health care utilization and cost to the health care system for vancomycin vs daptomycin in the outpatient setting and find that vancomycin results in significantly higher health care utilization and similar cost per course compared with daptomycin in OPAT.

Keywords: OPAT; antimicrobial stewardship; cost analysis; daptomycin; vancomycin.